UK Markets closed

Orchard Therapeutics plc (ORTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.4500-0.0500 (-3.33%)
At close: 4:00PM EST

Orchard Therapeutics plc

108 Cannon Street
London EC4N 6EU
United Kingdom
44 20 3 808 8286

Full-time employees224

Key executives

NameTitlePayExercisedYear born
Dr. Bobby Gaspar Ph.D., M.D.CEO, Member of Scientific Advisory Board & Exec. Director712.41kN/A1965
Mr. Frank E. ThomasPres & COO586.18kN/A1970
Dr. Nicoletta Loggia Ph.D.Chief Technical OfficerN/AN/AN/A
Ms. Renee T. LeckDirector of Investor RelationsN/AN/AN/A
Mr. John IlettChief of Staff, Chief Legal Officer & Company Sec.N/AN/AN/A
Benjamin NavonDirector of Corp. CommunicationsN/AN/AN/A
Mr. John CerioChief Human Resource OfficerN/AN/AN/A
Dr. Fulvio Mavilio Ph.D.Exec. OfficerN/AN/AN/A
Dr. Anne Dupraz-PoiseauChief Devel. OfficerN/AN/AN/A
Mr. Robin KenselaarSr. VP & GM of EMEA Commercial OperationsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Corporate governance

Orchard Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.